Department of Medicine, Pennsylvania Hospital, University of Pennsylvania Health System (UPHS), Philadelphia, PA, USA.
Department of Cardiology, Pennsylvania Hospital, University of Pennsylvania Health System (UPHS), Philadelphia, PA, USA.
J Interv Cardiol. 2020 Dec 24;2020:2582938. doi: 10.1155/2020/2582938. eCollection 2020.
Transcatheter aortic valve replacement (TAVR) is an established treatment for severe, symptomatic, aortic stenosis (AS) in patients of all risk categories and now comprises 12.5% of all aortic valve replacements. TAVR is a less invasive alternative to traditional surgical aortic valve replacement (SAVR), with equivalent or superior outcomes. The use of TAVR has increased rapidly. The success and increase in use of TAVR are a result of advances in technology, greater operator experience, and improved outcomes. Indications have recently expanded to include patients considered to be at low risk for SAVR. While TAVR outcomes have improved, remaining challenges include the management of coexistent coronary artery disease, prevention of periprocedural stroke, and issue of durability. These issues are even more relevant for low-risk, younger patients.
经导管主动脉瓣置换术（TAVR）是一种成熟的治疗方法，适用于所有风险类别的严重、有症状的主动脉瓣狭窄（AS）患者，目前占所有主动脉瓣置换术的 12.5%。TAVR 是一种较传统的外科主动脉瓣置换术（SAVR）更为微创的替代方法，具有同等或更好的效果。TAVR 的应用迅速增加。TAVR 的成功和应用的增加是技术进步、更多的操作人员经验和更好的结果的结果。适应证最近已扩大到包括被认为低危的 SAVR 患者。虽然 TAVR 的结果已经改善，但仍然存在一些挑战，包括并存的冠状动脉疾病的管理、预防围手术期中风以及耐久性问题。这些问题对于低危、年轻的患者更为重要。
